For reference only; not available for CME credit
Welcome to Part 1 of the 2-part case-based series.
New Currents in Treatment of Bone Metastases: A Case-Based Approach
This Tx Reporter series discusses the use of bisphosphonates to help prevent skeletal-related events in patients with bone metastases from urologic tumors. This first issue includes the case of a 62-year-old who presents with T1c prostate cancer that progresses to hormone-refractory metastatic disease.
This continuing professional education activity also includes the enclosed audio CD, in which Dr. Higano discusses:
- Osteoblastic bone disease and effects of hormonal prostate cancer therapies on bone
- The relationship between PSA level and bone metastases
- Early trials of clodronate and pamidronate in prostate cancer
- Recent data from the large study of zoledronic acid in hormone-refractory metastatic prostate cancer
- Treatment of hormone-naive prostate cancer patients with bone metastases
- The significance of bone resorption markers
- The potential role of bisphosphonates in nonmetastatic disease, including patients on hormone therapy
Dear Colleague:
For men with localized prostate cancer, 5-year survival rates are excellent (100%), but survival drops dramatically (34% at 5 years) once the disease has metastasized. About 90% of patients with advanced prostate cancer develop bone metastases, which are often the sole site of disease spread in prostate cancer. Bone metastases can cause considerable pain, spinal cord compression, and pathologic fractures. Recent data indicate that bisphosphonates, particularly zoledronic acid, can reduce the risk of skeletal complications when used as adjunctive therapy in the treatment of prostate cancer metastatic to bone.
This 2-part
Tx Reporter series,
New Currents in Treatment of Bone Metastases: A Case-Based Approach, presents an in-depth look at the data on bisphosphonates in patients with urologic cancers. In this
Tx Reporter, Dr. Higano illustrates how these data can be applied to an actual patient who develops hormone-refractory prostate cancer (HRPC) with progressive bone disease. In Part 2, Allan Lipton, MD, describes new data and their applications in metastatic renal cancer.
Each issue is an independent CME activity consisting of a
Tx Reporter newsletter and an audio CD featuring an interview of the expert faculty on related issues. Each issue is also accompanied by a recent reprint with information that has largely determined the current standard of care. This series focuses on the next generation of bisphosphonate therapy. However, fair balance is critical to this discussion, and the faculty and I also present data on other bisphosphonates. I hope that you enjoy the series and find it helpful and informative.
Yours truly,
Chair
James R. Berenson, MD
Chief Executive Officer
Institute for Myeloma and Bone Cancer Research
Los Angeles, California |
|
 |
|
Faculty
Celestia S. Higano, MD
Associate Professor of Medicine and Urology
University of Washington
Seattle Cancer Center Alliance
Seattle, Washington
|
|
 |
top
Target Audience
This activity is designed for urologists and urologic healthcare professionals who treat patients with bone metastases.
Activity Goal
The goal of this activity is to provide an overview of bone metastases and the latest developments in preventing related skeletal complications using bisphosphonate therapies.
Learning Objectives
After completing this activity, the participant should be able to:
- Describe the complications imposed by bone metastases in the clinical management of prostate cancer.
- Discuss the safety and efficacy of currently available agents and next generation bisphosphonates.
- Consider the use of intravenous therapy in the treatment armamentarium to delay and reduce skeletal complications of bone metastases in patients with hormone-refractory prostate cancer.
top
CME Information
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies. Projects In Knowledge designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Successful completion for up to 1 hour of CME credit in this newsletter/CD activity requires a passing score of 70% or higher on the posttest. Full instructions for submission are included on the posttest.
CPE Information
Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to this program, for 1 contact hour (0.1 CEU), is 052-000-03-055-H01.
CE Information
The National Center for Advanced Medical Education (a division of CMEinfo.com) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. The National Center for Advanced Medical Education (a division of CMEinfo.com) designates this educational activity for 1.2 contact hours. Provider approved by the California Board of Registered Nursing, Provider Number 13776 for 1.2 contact hours.
top
Disclosure Information
The Disclosure Policy of Projects In Knowledge and The National Center for Advanced Medical Education (a division of CMEinfo.com) requires that faculty participating in a CME/CPE/CE activity disclose to the audience: any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation; any relationship with the commercial supporter of this activity; if discussion includes 1) therapies that are unapproved for use or investigational; 2) ongoing research; or 3) preliminary data. Faculty will disclose such discussion.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians’ Desk Reference (PDR).
James R. Berenson, MD, has received grant/research support from
Amgen Inc, Chugai Pharmaceuticals Company, Millennium Pharmaceuticals, Inc, and Novartis Pharmaceuticals Corporation.
Celestia S. Higano, MD, has received grant/research support from Abbott Laboratories, Abgenix, Inc, Amgen Inc, Aventis Pharmaceuticals, Cell Genesys, Inc, Cell Pathways, Inc, Dendreon, Eli Lilly and Company, Medarex, Inc, Novacea, Novartis Pharmaceuticals Corporation, TAP Pharmaceuticals Inc, Transgene, and Xcyte Therapies.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge or The National Center for Advanced Medical Education (a division of CMEinfo.com).
This CME/CPE activity is provided by Projects In Knowledge, and the CE activity is provided by The National Center for Advanced Medical Education (a division of CMEinfo.com) solely as an educational service. Please note that although faculty will discuss specific treatment modalities, neither Projects In Knowledge, the accredited and approved CME provider, nor The National Center for Advanced Medical Education (a division of CMEinfo.com), the accredited and approved CE provider, nor their CME/CE regulatory bodies, including the ANCC, endorse any of the modalities mentioned in the course of discussion. Specific patient care decisions are the responsibility of the healthcare professional caring for the patient.
This independent CME/CPE/CE activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Nurse Planner: Christine Wilson, PhD, APRN, BC, NP-C, Visiting Assistant Professor, University of South Florida, Tampa, Florida.
Christine Wilson, PhD, APRN, BC, NP-C, is on the speakers bureau of Bristol-Myers Squibb Company; and is a stock shareholder in Pfizer Inc.
Nurse Reviewer: Susan Bove, MSN, APRN, BC, Private Practice, Reading, Massachusetts.
Susan Bove, MSN, APRN, BC, has no significant relationships with industry.
top